Mylan Inc

Most Recent

  • uploads///Graph
    Miscellaneous

    Teva Can Benefit by Acquiring Allergan Generics

    The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

    By Margaret Patrick
  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Teva Pharmaceutical in 2017

    Following the completion of its acquisition of Allergan’s Actavis Generics business on August 2, 2016, Teva Pharmaceutical plans to focus on realizing the deal’s synergies in 2017.

    By Margaret Patrick
  • uploads///man _
    Basic Materials

    Election Over, Market Still Undecided

    We know the nation is politically divided, and now the market is showing us its split personality as well.

    By JP Gravitt
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Teva Stock Has Risen Significantly since November Lows: What’s Next?

    On January 5, 2018, Teva Pharmaceuticals (TEVA) closed at $19.2 per share, which was ~77% higher than its 52-week low of $10.8 reported on November 2, 2017.

    By Sarah Collins
  • uploads///Select Generic Pharma Companies Sales by Geo
    Healthcare

    What Are Biosimilars and Why Do They Benefit Generic Pharma?

    BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]

    By VanEck
  • uploads///medicine _
    Company & Industry Overviews

    Mylan Launches First Adcirca Generic, Stock Moves Up

    Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    This Space Presents a Market Opportunity for Valeant

    In Valeant’s 2Q16 earnings, Xifaxan reported a year-over-year (or YoY) increase in monthly prescriptions of about 28.0%.

    By Margaret Patrick
  • uploads///valuation
    Company & Industry Overviews

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.

    By Sarah Collins
  • uploads///pulse trace _
    Company & Industry Overviews

    Analyst Ratings for Endo International and Peers in August

    In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • uploads///featured image
    Company & Industry Overviews

    An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

    Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.

    By Daniel Collins
  • uploads///pill _
    Earnings Report

    What Analysts Recommend for Mylan before Q2 2018 Earnings

    Mylan (MYL) plans to release its Q2 results on August 8. Thirteen of the 20 analysts covering the stock have given it a “buy” or “strong buy.”

    By Sarah Collins
  • uploads///Part
    Company & Industry Overviews

    Wall Street Looks at Sales Forecasts for Mylan’s Fulphila

    According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.

    By Sarah Collins
  • uploads///Acq
    Company & Industry Overviews

    Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets

    Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

    By Seth Richards
  • uploads///Part
    Company & Industry Overviews

    Mylan’s Humira Biosimilar Opportunity in Europe

    On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Share of the US Generics Market Could Boost Its Stock

    Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.

    By Margaret Patrick
  • uploads///pill _
    Company & Industry Overviews

    FDA Rejects Mylan’s Generic Advair Again, Stock Falls

    On June 13, Mylan (MYL) announced that the FDA did not approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination.

    By Sarah Collins
  • uploads///Chart  EPS
    Miscellaneous

    Understanding Allergan’s Valuation after the 1Q17 Results

    On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.

    By Mike Benson
  • uploads///growth of generics
    Company & Industry Overviews

    Rx for Growth? Why Generic Drugs Are Gaining Traction

    Rx for Growth? The trillion-dollar pharmaceutical industry has historically been dominated by a few major companies that create and supply the most important branded prescriptions on the market. Recent trends, however, point to the growth of the newest pharma blockbusters: generics. Today, approximately 60% of Americans take prescription drugs;[1. “Trends in Prescription Drug Use Among […]

    By VanEck
  • uploads///inorganic growth
    Company & Industry Overviews

    Four Key Deals: Analyzing Pfizer’s Impending Growth

    Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

    By Margaret Patrick
  • uploads///COPAXONE
    Company & Industry Overviews

    Teva’s Copaxone Maintains Market Share amid Intense Competition

    In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Akorn’s Macro-Level Challenges in the Generic Drug Segment

    Although generic drugs only account for 3% of the total healthcare costs in the US, regulators continue to be concerned about rising generic pricing.

    By Margaret Patrick
  • uploads///Part
    Consumer

    David Einhorn Was Right about Apple

    Greenlight Capital (GLRE) exited its position in Apple in the third quarter of 2018.

    By Anuradha Garg
  • uploads///medical _
    Earnings Report

    Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results

    Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.

    By Sarah Collins
  • uploads///RD Generic Pharma
    Macroeconomic Analysis

    Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 2)

    (continued from Part 1) 4. What is the nature of the cash flows for generics companies? Stable, driven by a constant demand for prescription drugs? Or lumpy, driven by growth from drugs coming off patent? The larger companies in this sector tend to have stable, steadier cash flows due to established lineups of approved products. […]

    By VanEck
  • why did kodak stock jump
    Industrials

    Is Kodak Stock Worth Your Attention Right Now?

    By Ambrish Shah
  • uploads///Graph
    Company & Industry Overviews

    What Are Mylan’s Key Growth Drivers in Fiscal 2019?

    In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.

    By Margaret Patrick
  • uploads///Pfizer stock
    Company & Industry Overviews

    Why Pfizer Stock Continues to Tank after Mylan Deal

    Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.

    By Maitali Ramkumar
  • uploads///AdobeStock_
    Healthcare

    Pfizer and Mylan: Is Mega-Merger on the Horizon?

    The Wall Street Journal first announced the probable merger of Pfizer’s (PFE) off-patent business with Mylan (MYL) on July 27.

    By Margaret Patrick
  • uploads///hypertension _
    Company & Industry Overviews

    What Analysts Are Recommending for Teva Pharmaceutical This Month

    On February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price.

    By Margaret Patrick
  • uploads///Part  Earnings Q  Pre
    Consumer

    Can Stanley Black & Decker’s Q4 Earnings Beat the Estimates?

    Stanley Black & Decker (SWK) is expected to post an adjusted EPS of $2.1 in the fourth quarter—a decrease of ~4.7% YoY (year-over-year).

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?

    In the first nine months of 2018, Teva Pharmaceutical (TEVA) reduced its net debt level by $3.9 billion to $27.6 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical or Mylan: Which Is More Cost Optimal?

    According to Teva’s 37th Annual J.P. Morgan Healthcare Conference transcript, it reduced its spending base by $1.8 billion in the first nine months of 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva or Mylan: Whose Earnings Are Growing Faster?

    In its third-quarter earnings investor presentation, Teva Pharmaceutical forecast 2018 non-GAAP EPS of $2.80–$2.95.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva or Mylan: Who Has the More Promising Revenue Trajectory?

    In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) forecast total 2018 revenue in the range of $18.6 billion–$19.0 billion.

    By Margaret Patrick
  • uploads///Teva pharma
    Company & Industry Overviews

    A Financial Overview of Teva Pharmaceutical in December

    In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Teva Pharmaceutical Stock Rose More than ~8% on December 26

    On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.

    By Daniel Collins
  • uploads///bausch
    Company & Industry Overviews

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    What Are Pfizer’s Revenue Drivers?

    Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.

    By Mike Benson
  • uploads///medicine _
    Company & Industry Overviews

    Analyst Recommendations for Valeant Pharmaceuticals in July

    In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate.

    By Daniel Collins
  • uploads///tablets _
    Company & Industry Overviews

    Analyst Recommendations for Teva Pharmaceutical in July

    As of July 6, according to a recent Reuters survey, 28 analysts are tracking TEVA stock. Six of them have rated it a “buy” or “strong buy.”

    By Sarah Collins
  • uploads/// NON GAAP ADJUSTMENTS
    Company & Industry Overviews

    US Generics Market Consolidation Continues to Affect Teva

    In 4Q17, Teva experienced a price erosion of ~13% in its generics business.

    By Sarah Collins
  • uploads///valeants top  drugs
    Company & Industry Overviews

    How the Market Reacted to Teva’s Pricing of Its Generic Syprine

    On February 9, 2018, Teva Pharmaceuticals (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    These Pfizer Products Saw Declining Sales in 4Q17

    A few products in Pfizer’s (PFE) portfolio reported declining sales in 4Q17 following their loss of market share to the competition.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Sandoz Performed in 4Q17

    Sandoz reported flat revenues at ~$2.6 billion during 4Q17 as compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi Pasteur’s 4Q17 Performance

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17, reflecting 8.7% growth in operating revenues compared to 4Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline

    Trelegy Ellipta could enable GlaxoSmithKline to compete aggressively with other respiratory players such as Novartis (NVS).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anoro Ellipta May Boost GlaxoSmithKline’s Respiratory Franchise Revenues

    Anoro Elipta earned revenues of close to 233 million pounds in the first nine months of 2017, which is 77% year-over-year (or YoY) growth on a reported basis and 63% YoY growth on a constant exchange rate (or CER) basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment

    To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Has Developed a Broad Respiratory Portfolio

    In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.6 billion pounds from the sale of its respiratory products, which is year-over-year (or YoY) growth of 1% on a reported basis.

    By Margaret Patrick
  • uploads///Chart  AH
    Company & Industry Overviews

    Merck & Co.’s Animal Health Business in 3Q17

    Merck’s (MRK) Animal Health segment’s total revenues increased ~16% to $1 billion in 3Q17 compared to $865 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Revenue Estimates for 4Q17

    Johnson & Johnson’s (JNJ) Pharmaceutical segment contributes more than 45% to total revenues. In 4Q17, it’s expected to report growth in operating revenues.

    By Mike Benson
  • uploads///financial profile
    Company & Industry Overviews

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Teva Pharmaceutical has implemented a clear strategy to improve its financial profile and establish long-term growth prospects.

    By Sarah Collins
  • uploads///new organizational structure
    Company & Industry Overviews

    How Teva Pharmaceutical Is Realigning Organizational Structure

    On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years.

    By Sarah Collins
  • uploads///TEVAS CURRENT REALITY
    Company & Industry Overviews

    The Key Challenges Teva Pharmaceutical Is Facing

    In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5%.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Wall Street Recommendations for Mylan in January 2018

    As we discussed earlier in this series, Mylan (MYL) reported revenues of $2.98 billion in 3Q17, a 2.3% decline in revenues compared to $3.06 billion in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Developments for Mylan

    Recent developments reported by Mylan (MYL) include commercial developments as well as product developments. Let’s take a closer look.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Mylan’s Rest of the World Segment Performed in 3Q17

    Mylan’s (MYL) Rest of the World segment includes revenues from third-party sales of generics products and specialty segment products reported from countries including New Zealand, India, Japan, and Australia as well as emerging markets including Asia, Brazil, Africa, and the Middle East.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Valuation in January 2018

    Mylan (MYL) is a leading pharmaceutical company with over 1,400 generic and specialty pharmaceutical products in its portfolio.

    By Mike Benson
  • uploads///Mylan Risks
    Company & Industry Overviews

    Key Risks Facing Mylan in January 2018

    Key risks Mylan (MYL) has diversified its operations across multiple product categories and geographies. However, there are certain company-specific risks that may affect its profitability in 2018. In 2011, Mylan entered into an agreement with Pfizer (PFE), allowing the former exclusive worldwide rights to develop, manufacture, and commercialize Pfizer’s generic versions of GlaxoSmithKline’s (GSK) Advair and […]

    By Kenneth Smith
  • uploads///Q segment performance
    Company & Industry Overviews

    Exploring Mylan’s Diversified Portfolio of Brands

    Product portfolio Mylan’s (MYL) portfolio of branded products includes Creon, Influvac, Dymista, Dona, Betadine, Saugella, and EpiPen. Mylan has a favorable product mix of generic, brand name, and over-the-counter products catering to different therapeutic areas and sold in multiple geographies. Mylan launched Imatinib tablets in the United States in 2017, strengthening its US oncology portfolio, […]

    By Kenneth Smith
  • uploads///Mylan Analysts estimates
    Company & Industry Overviews

    Analysts’ Recommendations for Mylan

    Mylan (MYL), which has a global presence, is focused on developing, manufacturing, and distributing generic, brand name, and over-the-counter products in various therapeutic categories.

    By Kenneth Smith
  • uploads///Chart  New
    Company & Industry Overviews

    Eli Lilly’s New Products Portfolio in 3Q17

    Eli Lilly and Co.’s (LLY) product portfolio includes Basaglar, Jardiance, Cyramza, Lartruvo, Taltz, Olumiant, and Trulicity.

    By Mike Benson
  • uploads///NET SALES EPS GROWTH MYL
    Consumer

    Mylan: How Its Performance Contributed to Its Valuation

    In this final series of our three-part series, we’ll be looking at the last seven stocks among the top 18 cheap stocks in the S&P 500 for 2018.

    By Amanda Lawrence
  • uploads///Baby
    Company & Industry Overviews

    How JNJ’s Baby Care, Beauty, and OTC Products Performed in 3Q17

    In 3Q17, Johnson & Johnson’s (JNJ) baby care products generated revenues of $477 million, a ~4% decline on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  Keytruda Revenues
    Company & Industry Overviews

    Keytruda: Driving Merck’s Growth

    For 3Q17, Keytruda reported revenues of ~$1.1 billion, a 194% growth compared to revenues of $356 million in 3Q16.

    By Mike Benson
  • uploads///Part  Recommendations
    Basic Materials

    Wall Street Talks: Albemarle’s Target Prices by Analyst

    As of November 28, 2017, 38% of the 21 analysts covering Albemarle (ALB) stock have recommended a “buy” for the stock, and 62% have recommended a “hold.”

    By Peter Neil
  • uploads///XYOSTED Profile
    Company & Industry Overviews

    Exploring Antares Pharma’s Current Pipeline of Products

    On October 11, 2017, Antares Pharma (ATRS) was notified by the FDA that it had found deficiencies in Xyosted.

    By Kenneth Smith
  • uploads///Part  Recommendations
    Basic Materials

    Wall Street’s View on Albemarle after 3Q17 Earnings Release

    After Albemarle (ALB) posted its 3Q17 earnings, 20 analysts have been actively tracking the stock. About 45% of them have recommended a “buy” for the stock.

    By Peter Neil
  • uploads///Chart  NGC
    Earnings Report

    These Pfizer Products Lost Market Share in 3Q17

    BeneFIX revenues fell 14% to $151 million during 3Q17, driven by a 16% fall in international sales to $87 million.

    By Mike Benson
  • uploads///gAINERS
    Company & Industry Overviews

    Mylan: S&P 500’s Top Gainer on October 4

    Mylan, which is one of the leading global pharmaceutical companies in the world, was the S&P 500’s top gainer on October 4.

    By Val Kensington
  • uploads///Graph
    Company & Industry Overviews

    Could Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver?

    According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.

    By Margaret Patrick
  • uploads///graph_
    Company & Industry Overviews

    Could Mylan See a Rise in Net Profit Margins in 2017?

    In 2Q17, Mylan (MYL) reported gross profit margins of 54.0%, which was lower than 56.0% reported in 2Q16.

    By Margaret Patrick
  • uploads///Generics revenues
    Company & Industry Overviews

    How TEVA’s Generic Medicines Franchise Is Positioned after 1H17

    In 1H17, Teva Pharmaceutical’s (TEVA) generic medicines business generated revenues of ~$6.1 billion, or ~22% higher YoY (year-over-year).

    By Daniel Collins
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Behind the Latest Developments for Merck’s Keytruda

    Keytruda (pembrolizumab) is a prescription medicine from Merck’s (MRK) immuno-oncology franchise used for the treatment of various tumors.

    By Mike Benson
  • uploads///Xyrem
    Company & Industry Overviews

    This Could Drive Jazz Pharmaceuticals’ Revenue Growth

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of ~$298 million, which represents ~6% growth YoY and ~10% growth QoQ.

    By Daniel Collins
  • uploads///SIP
    Company & Industry Overviews

    Pfizer’s Sterile Injection Pharmaceuticals in 2Q17 and 1H17

    In 1H17, Sulperazon reported revenues of ~$232 million for 15% growth on a YoY basis.

    By Daniel Collins
  • uploads///Chart  Segment
    Company & Industry Overviews

    Performance of Eli Lilly’s Business Segments in 2Q17

    The Human Pharmaceuticals segment reported revenues of ~$5.0 billion during 2Q17, representing 10.9% growth compared to its 2Q16 revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s 2Q17 Performance, by Segment

    Segment-wise performance Johnson & Johnson (JNJ) reported 2.9% growth in operating revenue between 2Q16 and 2Q17. However, the company missed analysts’ 2Q17 estimate and reported revenue of $18.8 billion due to a 1% foreign exchange impact. Analysts had forecast revenue of $19 billion. Johnson & Johnson’s business is broken down into the pharmaceuticals segment, consumer […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Inside the Efficacy of JAZZ’s JZP-110 in Obstructive Sleep Apnea Trials

    This trial demonstrated the efficacy and safety of JAZZ’s JZP-110 in both the MWT and sleep latency tests at all dosages at the end of weeks 4 and 12.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Future of JAZZ’s Low-Sodium Investigational Drugs

    A 9-mg dose of JAZZ’s Xyrem, which contains 1,640 mg of sodium, has caused physicians to be reluctant to prescribe the drug to ~20% of their patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Alone Could Boost Xyrem’s Addressable Market in 2018

    To expand Xyrem’s addressable market, JAZZ has been evaluating the efficacy of Xyrem in pediatric narcolepsy patients with cataplexy and excessive sleepiness.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Xyrem’s Solid Demand Trends in 2017

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.

    By Margaret Patrick
  • uploads///Chart  Pharmaceutical
    Earnings Report

    Johnson & Johnson: Pharmaceuticals in 2Q17

    Pharmaceutical segment Johnson & Johnson’s (JNJ) pharmaceutical segment comprises its immunology, infectious disease, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension franchises. Immunology franchise The major blockbuster drugs under the immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria. The immunology franchise reported revenue of $3 billion in 2Q17, including an operational decrease of ~1.9% and a […]

    By Mike Benson
  • uploads///Chart  EPS
    Company & Industry Overviews

    What Allergan’s Valuation as of July 13 Tells Us

    For 2Q17, Wall Street analysts estimate AGN’s EPS (earnings per share) to come in at $3.93, which would be a 17.5% growth over 2Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be a Major Growth Driver for Regeneron in 2017

    After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

    By Margaret Patrick
  • uploads///Chart  Humalog
    Company & Industry Overviews

    FDA Approves Eli Lilly’s Humalog Junior KwikPen

    Eli Lilly (LLY) announced that the US Food and Drug Administration (or FDA) approved the Humalog Junior KwikPen for finer dose adjustments in the treatment of patients with diabetes on June 13, 2017.

    By Mike Benson
  • uploads///Chart  Neuro
    Earnings Report

    Eli Lilly’s Estimate for Strattera, Other Neuroscience Products

    Neuroscience is one of Eli Lilly’s (LLY) franchises in its human pharmaceutical segment. Key drugs in this segment include Zyprexa, Cymbalta, and Strattera.

    By Mike Benson
  • uploads///Chart  ABT
    Miscellaneous

    Analyzing the Performance of Abbott Laboratories in 1Q17

    Abbott Laboratories’ stock price rose ~7.1% in 1Q17. On April 7, 2017, the stock’s price had risen 13.7% year-to-date (or YTD).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Contributed to Pfizer’s Growth in 2016?

    The key performers of Pfizer’s product portfolio include Lyrica, Ibrance, Xeljanz, and Eliquis from the Innovative Health business.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Pfizer’s Growth Contributors in 4Q16

    The key performers in Pfizer’s (PFE) product portfolio include Lyrica, Ibrance, Xeljanz, and Eliquis, which are in the company’s Innovative Health business.

    By Mike Benson
  • uploads///Chart  Neuro
    Earnings Report

    How Will Eli Lilly’s Neuroscience Franchise Fare in 4Q16?

    The neuroscience franchise contributes over ~13% of Lilly’s total revenues. Key drugs in this segment include Zyprexa, Cymbalta, and Strattera.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Is Mylan’s Generics Segment Doing?

    Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s EpiPen Controversy: Is It a Brand or a Generic?

    Mylan has been embroiled in a controversy over whether its EpiPen is classified as a generic or a branded product and whether its 500.0% price hike is justified.

    By Mike Benson
  • uploads///financial terms
    Company & Industry Overviews

    Financial Metrics of Baxter’s Acquisition of Claris Injectables

    The injectables business of Claris Lifesciences comprises 70.0%–80.0% of its total sales. Claris plans to repatriate about 85.0% of the generated funds to its shareholders.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Valuation Compared to Its Peers

    Allergan’s stock value fell more than 40% over the last 12 months. Analysts estimate that the stock could to return ~39.5% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of key drug Eliquis. This segment contributed nearly 18% of total revenues for 3Q16.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.